Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
At P-Values, you’ll find updates, perspective, insights and information from staff and partners working on the frontlines of research, advocacy and implementation. P-value is a statistical term for the probability that a trial result is reliable and not the outcome of chance.
Blog Post
In response to the US government’s August 26 emergency application to the US Supreme Court seeking to stay the preliminary injunction in the AVAC v Department of State legal case against the foreign aid freeze, AVAC’s Executive Director, Mitchell Warren, asks whether SCOTUS will restore some of the checks and balances this administration is consistently undermining.
Blog Post
The drug maker Merck’s recent announcement of two new efficacy trials of a monthly PrEP pill, known as the EXPrESSIVE program, is welcome news. In addition, Merck’s robust commitment to stakeholder engagement to date contributes an important model of Good Participatory Practice (GPP) to the field, by putting global advocates at the forefront of planning for the program.
Blog Post
This week brought another round of threats and attacks on US global health policy including troubling court rulings over the foreign aid freeze, deepening cuts to the fiscal year 2026 (FY26) global health budget, and troubling developments at NIH, where new research priorities and another agency-wide review could disrupt HIV and global health research. We also track new signals of a US pullback at UN General Assembly (UNGA).
showing 1-10 of 1123
In response to the US government’s August 26 emergency application to the US Supreme Court seeking to stay the preliminary injunction in the AVAC v Department of State legal case against the foreign aid freeze, AVAC’s Executive Director, Mitchell Warren, asks whether SCOTUS will restore some of the checks and balances this administration is consistently undermining.
The drug maker Merck’s recent announcement of two new efficacy trials of a monthly PrEP pill, known as the EXPrESSIVE program, is welcome news. In addition, Merck’s robust commitment to stakeholder engagement to date contributes an important model of Good Participatory Practice (GPP) to the field, by putting global advocates at the forefront of planning for the program.
Prevention Option:
This week brought another round of threats and attacks on US global health policy including troubling court rulings over the foreign aid freeze, deepening cuts to the fiscal year 2026 (FY26) global health budget, and troubling developments at NIH, where new research priorities and another agency-wide review could disrupt HIV and global health research. We also track new signals of a US pullback at UN General Assembly (UNGA).
This issue covers the Appeals Court opinion in AVAC v Department of State, a violent attack on the CDC fueled by vaccine disinformation, the continued dismantling of the NIH with a potential pendulum swing toward implementation science and away from basic science and clinical research, and a new executive order politicizing federal grants.
AVAC strongly condemns today’s decision by the U.S. Court of Appeals for the D.C. Circuit to overturn the District Court’s injunction that compelled the restoration of vital foreign aid funding in the lawsuit, AVAC v. United States Department of State, which challenged the Trump Administration’s funding freeze on foreign assistance.
This week the US administration cancelled $500 million in mRNA vaccine contracts while a Government Accountability Office investigation found the NIH grant freezes violated the law. The Gates Foundation committed $2.5 billion to women’s health R&D, and South Africa is investing to protect its national research capacity in the face of US funding cuts.
The STI & HIV World Congress brought together over 1,400 researchers, healthcare providers, advocates, funders and more in Montreal last week, where they shared urgent insights, promising innovations, and calls to action. The gathering came at a pivotal moment when rates of STIs are rising globally, amid massive disruptions caused by shifts in US policies and funding and decreased investments from other funders.
AVAC condemns a series of actions taken by the U.S. presidential administration to dismantle U.S. leadership in research, development and delivery of lifesaving vaccines. Without U.S. government leadership, the country and the world will remain woefully unprepared for ongoing and emerging pandemic threats.
Last Friday, the European Medicines Agency recommended injectable lenacapavir for PrEP. This comes amid more political chaos this week that threatens delivery including, a surprise funding freeze and its reversal, a new whistleblower report on the unlawful foreign aid freeze, changes in NIH policies and continued dismantling of federal advisory boards.
Momentum continues to build for injectable lenacapavir (LEN) for PrEP as what could be one of the most transformational moments in HIV prevention ever. Check out AVAC’s resources below (all newly updated) to help advocates track, explain, and take action to meet the moment.
showing 1-10 of 1123
Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
AVAC’s email list for organization and individuals interested in timely updates and critical perspectives on developments in biomedical HIV prevention.
A comprehensive round-up of HIV prevention media coverage and scientific publications.
Each month this podcast uses interviews, discussion and first-person reflections to explore vital topics confronting the field of HIV prevention research.
PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.
Pandemic Watch is a curated news digest on the latest pandemic prevention, preparedness, and response (PPPR) news and resources.
A collection of official statements from AVAC.
Media clippings featuring AVAC, its staff and close partners in the news media.